Neovascular (WET) age-related macular degeneration (NAMD)

Clinical trials for Neovascular (WET) age-related macular degeneration (NAMD) explained in plain language.

Never miss a new study

Get alerted when new Neovascular (WET) age-related macular degeneration (NAMD) trials appear

Sign up with your email to follow new studies for Neovascular (WET) age-related macular degeneration (NAMD), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Completed 1

One-Time gene injection could end frequent eye shots for wet AMD

Disease control Completed

This early-stage trial tested a gene therapy called EXG102-031 in 12 people with wet age-related macular degeneration (nAMD), a condition where abnormal blood vessels damage central vision. The therapy was injected into the eye to block these vessels. The main goal was to check s…

Matched conditions: NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION (NAMD)

Phase 1 • Sponsor: Exegenesis Bio • Aim: Disease control

Last updated Jun 27, 2026 12:06 UTC

Neovascular (WET) age-related macular degeneration (NAMD)

Get alerted when new Neovascular (WET) age-related macular degeneration (NAMD) trials appear

One-Time gene injection could end frequent eye shots for wet AMD